These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

305 related items for PubMed ID: 1992188

  • 21. [Orphan drugs--medications for patients with rare diseases].
    Thielke D, Thyssen JP, Hansen BJ.
    Ugeskr Laeger; 2006 Jun 05; 168(23):2236-8. PubMed ID: 16768975
    [Abstract] [Full Text] [Related]

  • 22. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA, Freeman SN, Imoisili MA, Coté TR.
    Clin Pharmacol Ther; 2010 Oct 05; 88(4):449-53. PubMed ID: 20856241
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Navigating through orphan medicinal product regulations in EU and US--similarities and differences.
    Tiwari J.
    Regul Toxicol Pharmacol; 2015 Feb 05; 71(1):63-7. PubMed ID: 25497996
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G.
    Wall St J (East Ed); 2005 Nov 15; ():A1, A18. PubMed ID: 16502531
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. History of Orphan Drug Regulation-United States and Beyond.
    Haffner ME.
    Clin Pharmacol Ther; 2016 Oct 15; 100(4):342-3. PubMed ID: 27392514
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec 15; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Orphan drugs and orphan tests in the USA.
    Thoene JG.
    Community Genet; 2004 Dec 15; 7(4):169-72. PubMed ID: 15692190
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E.
    Orphanet J Rare Dis; 2017 Jan 05; 12(1):1. PubMed ID: 28057032
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.